Celgene

Person

Mentions

Relationships

Events

Documents

Relationship Network

Network Depth

Loading... nodes

Interactive Network: Click nodes or edges to highlight connections and view details with action buttons. Drag nodes to reposition. Node size indicates connection count. Line color shows relationship strength: red (8-10), orange (6-7), yellow (4-5), gray (weak). Use legend and help buttons in the graph for more guidance.

Event Timeline

Interactive Timeline: Hover over events to see details. Events are arranged chronologically and alternate between top and bottom for better visibility.

18 total relationships

Sort by:

Connected Entity	Relationship Type	Strength (mentions)	Documents	Actions
person Mr. Hugin	Employment	7	1	View
person F.D.A.	Regulatory oversight adversarial	7	1	View
person Mr. Hugin	Executive company	7	1	View
person the agency	Regulated entity regulator	6	1	View
person F.D.A.	Regulated by	6	1	View
person Revlimid	Unknown	5	1	View
person Thalomid	Unknown	5	1	View
organization Mylan	Unknown	5	1	View
organization Lannett	Unknown	5	1	View
organization Mylan	Legal representative	5	1	View
organization Lannett	Legal representative	5	1	View
person Elaine Kodish	Patient manufacturer	5	1	View
person Bob Hugin	Employment	5	1	View
person Michael Carrier	Expert critic	5	1	View
person Bob Hugin	Former executive	5	1	View
person Bob Hugin	Employee	5	1	View
person F.D.A.	Regulated entity regulator	5	1	View
person Mr. Hugin	Employee	5	1	View

Date	Event Type	Description	Location	Actions
N/A	N/A	Mr. Hugin, a managing director at J.P. Morgan, was hired by Celgene as a top executive.	N/A	View
N/A	N/A	Celgene used the REMS (Risk Evaluation and Mitigation System) program to restrict access to its d...	N/A	View
N/A	N/A	Celgene raised the price of a month's supply of Revlimid to more than $16,000.	N/A	View
2025-03-01	N/A	Celgene hired a team of 60 sales representatives, many with experience in oncology, and announced...	N/A	View
2017-01-01	N/A	Celgene settled a lawsuit regarding illegal marketing to avoid protracted litigation.	N/A	View
2017-01-01	N/A	Celgene settled a whistle-blower lawsuit concerning its marketing practices.	N/A	View
2007-01-01	N/A	Celgene reported that only about 100 prescriptions per year were written for the approved skin co...	United States	View
2007-01-01	N/A	Celgene reported that only 100 prescriptions a year were being written for Thalomid to treat the ...	United States	View
2006-01-01	N/A	Revlimid was introduced to the market at an initial cost of about $6,000 per month.	N/A	View
2005-01-01	N/A	Celgene received formal approval to market Thalomid and Revlimid for certain cancers.	N/A	View
2001-01-01	N/A	Celgene reported that 92 percent of Thalomid's prescriptions were being written to treat cancer, ...	N/A	View
1999-06-01	N/A	Mr. Hugin arrived at Celgene while the company was struggling to profit from its only drug, Thalo...	New Jersey	View
1999-01-01	N/A	Mr. Hugin arrived at Celgene, which was struggling to profit from its only marketed drug, Thalomid.	New Jersey	View
1998-12-01	N/A	The F.D.A. held a meeting to warn Celgene about its marketing of Thalomid for unapproved uses.	N/A	View
1998-01-01	N/A	The F.D.A. approved Celgene's application to treat erythema nodosum leprosum, a complication of l...	United States	View
1998-01-01	N/A	Celgene's application was approved by the F.D.A. to treat erythema nodosum leprosum, a complicati...	United States	View

No documents found for this entity.

Total Received

$13,400,000,000.00

1 transactions

Total Paid

$560,066,000.00

8 transactions

Net Flow

$12,839,934,000.00

9 total transactions

Date	Type	From	To	Amount	Description	Actions
2019-08-27	Received	Amgen	Celgene	$13,400,000,000.00	Purchase of psoriasis drug Otezla.	View
2017-07-25	Paid	Celgene	Not specified	$280,000,000.00	Payment to Settle Fraud Suit Over Cancer Drugs,...	View
2017-07-25	Paid	Celgene	Not specified	$280,000,000.00	Payment to Settle Fraud Suit Over Cancer Drugs,...	View
2017-01-01	Paid	Celgene	Patients/Market	$16,000.00	Price for a month's supply of Revlimid after Ce...	View
2017-01-01	Paid	Celgene	Patients/Market	$16,000.00	Price for a month's supply of Revlimid after Ce...	View
2017-01-01	Paid	Celgene	Patients/Market	$16,000.00	Price for a month's supply of Revlimid after Ce...	View
2006-01-01	Paid	Celgene	Patients/Market	$6,000.00	Initial cost for a month's supply of Revlimid w...	View
2006-01-01	Paid	Celgene	Patients/Market	$6,000.00	Initial cost for a month's supply of Revlimid w...	View
2006-01-01	Paid	Celgene	Patients/Market	$6,000.00	Initial cost for a month's supply of Revlimid w...	View

As Sender

As Recipient

Total

Request for drug samples for generic development

From: Generic drug companies...

To: Celgene

The document describes a pattern of communication where Celgene would refuse to distribute drug samples, citing REMS, and demand written confirmation from the F.D.A. After generic companies provided this, Celgene would then request more 'laborious, irrelevant and time consuming' information to further delay the process.

Process

N/A

Communication Source

Future dependency on Thalomid

From: Celgene

To: local and regional inv...

Celgene warned investors that the company would be 'very dependent on the commercial success of Thalomid' and that its approved market was 'relatively small'.

Warning to investors

N/A

Communication Source

Multiple Myeloma

From: Celgene

To: Public

Celgene announced it would pursue F.D.A. approval for multiple myeloma. The F.D.A. later reprimanded them for not adequately warning about thalidomide's risks in this announcement.

Company announcement

N/A

Communication Source

Future dependency on Thalomid

From: Celgene

To: local and regional inv...

Celgene warned investors that the company would be 'very dependent on the commercial success of Thalomid' and that its approved market was 'relatively small'.

Warning to investors

N/A

Communication Source

Future dependency on Thalomid

From: Celgene

To: local and regional inv...

Celgene warned investors that the company would be 'very dependent on the commercial success of Thalomid' and that its approved market was 'relatively small'.

Warning to investors

N/A

Communication Source

Multiple Myeloma

From: Celgene

To: Public

Celgene announced it would pursue F.D.A. approval for multiple myeloma. The F.D.A. later reprimanded them for not adequately warning about thalidomide's risks in this announcement.

Company announcement

N/A

Communication Source

Multiple Myeloma

From: Celgene

To: Public

Celgene announced it would pursue F.D.A. approval for multiple myeloma. The F.D.A. later reprimanded them for not adequately warning about thalidomide's risks in this announcement.

Company announcement

N/A

Communication Source

Formal Warning for Improper Marketing

From: the agency

To: Celgene

A formal warning letter stating Celgene was improperly marketing Thalomid for various cancers and to promote a feeling of 'general well-being' in cancer patients.

Letter

2000-01-01

Communication Source

Formal Warning for Improper Marketing

From: the agency

To: Celgene

A formal warning letter stating Celgene was improperly marketing Thalomid for various cancers and to promote a feeling of 'general well-being' in cancer patients.

Letter

2000-01-01

Communication Source

Formal Warning for Improper Marketing

From: the agency

To: Celgene

A formal warning letter stating Celgene was improperly marketing Thalomid for various cancers and to promote a feeling of 'general well-being' in cancer patients.

Letter

2000-01-01

Communication Source